Journal of Cancer Research and Clinical Oncology

, Volume 123, Issue 9, pp 469–477 | Cite as

Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment

  • K. Junker
  • M. Thomas
  • K. Schulmann
  • F. Klinke
  • U. Bosse
  • K. -M. Müller
Original Paper


In the scope of a prospective multi-centre study after neoadjuvant combined chemotherapy (carboplatin, ifosfamide, etoposide, vindesine) and radiotherapy (45 Gy) 40 resection specimens of locally advanced non-small-cell lung cancer were analysed in order to establish reproducible pathological/anatomical results of tumour regression. Resection specimens of 28 squamous cell carcinomas and 12 adenocarcinomas were investigated using serial sections of the primary lesion. The mean age of the patients was 57 years. The results were compared to spontaneous regressive changes in a control group of 50 untreated non-small-cell lung cancers. Marked scarry fibrosis in the region of the former primary tumour, concentric foci of fresh tumour necroses and surrounding foam cell clusters with transition into vascular granulation tissue could be established as characteristic features of therapy-induced tumour regression, whereas untreated carcinomas revealed necroses with adjoining vital tumour tissue. Using a threestep regression system, 3 tumours could be classified as grade I (no or only slight tumour regression), 10 tumours as grade IIA (marked but incomplete tumour regression, more than 10% vital tumour tissue), 20 tumours as grade IIB (less than 10% vital tumour tissue) and 7 tumours as grade III (complete tumour regression without vital tumour tissue). After a median follow-up period of 32.3 months in patients with grade IIB or III tumour regression (“responders”) the median survival time of 27.9 months was found to be significantly longer than in patients with grade I or IIA tumour regression (“non-responders”) with a median survival period of 13.7 months (log-rank test,P=0.020). The resection specimens analysed, which were obtained 7 weeks (on average) after the end of radiochemotherapy, did not show specific changes due to preoperative therapy, but quite characteristic histological alterations in the former tumour area were registered, which had been induced by combined neoadjuvant radiation and chemotherapy. The grade of therapy-induced tumour regression could be shown to be a significant prognostic factor in non-small-cell lung cancer.

Key words

Non-small-cell lung cancer Neoadjuvant therapy Regression grading Therapy-induced tumour regression Spontaneous tumour regression 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Al-Kourainy, Kish J, Ensley J, Tapazoglou E, Jacobs J, Weaver A, Crissman J, Cummings G, Al-Sarraf (1987) Achievement of superior survival for histologically negative versus positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 59:233–238PubMedGoogle Scholar
  2. Becker K, Fink U, Siewert JR, Höfler H (1996) Morphological effects of preoperative chemotherapy in locally advanced adenocarcinoma of the stomach (T3/T4) with EAP (etoposid, Adriamycin, cis-platin). Pathol Res Pract 192:341Google Scholar
  3. Böheim K, Mikuz G, Böheim C (1982) Pathohistologische Veränderungen nach zytostatischer Induktionstherapie mit Methotrexat, Bleomycin und Cis-Platinum. Laryngol Rhinol Otol 61:246–250Google Scholar
  4. Bromley LL, Szur L (1955) Combined radiotherapy and resection for carcinoma of the bronchus. Lancet 1955:937–941Google Scholar
  5. Burkes RL, Ginsberg RJ, Shepherd FA (1992) Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 10:580–586PubMedGoogle Scholar
  6. Dabbs DJ (1993) Mammary ductal foam cells: macrophage immunophenotype. Hum Pathol 24:977–981PubMedGoogle Scholar
  7. Dhom G, Degro S (1982) Therapy of prostatic cancer and histopathologic follow-up. Prostate 3:531–542PubMedGoogle Scholar
  8. Eagan R, Ruud C, Lee R (1987) Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancer. Cancer Treat Rep 71:895–900PubMedGoogle Scholar
  9. Edelmann MJ, Gandara DR, Roach M, Benfield JR (1996) Multimodality therapy in stage III non-small cell lung cancer. Ann Thorac Surg 47:669–675Google Scholar
  10. Eiff M von, Geiger A, Wagner W, Rübe C, Klinke V, Thomas M, Loo J van de (1994) Neoadjuvant chemo-/radiotherapy in locally advanced non-small cell lung cancer. In: Rao RS, Deo MG, Sanghvi LD (eds) Proceedings of the 16th International Cancer Congress, Monducci, Bologna 1994. pp 1187–1190Google Scholar
  11. Faber LD, Kittle CF, Warren WT (1989) Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 47:669–677PubMedGoogle Scholar
  12. Fischer HP (1985) Therapieinduzierte Tumorregression — Morphologische Befunde an malignen primären und sekundären Lebertumoren nach hochdosierter regionaler Zytostase. Pathologe 6:16–23PubMedGoogle Scholar
  13. Gerrity RG (1981) The role of monocyte in atherosclerosis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 103:181–190PubMedGoogle Scholar
  14. Green S, Weiss GR (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. West New Drugs 10:243–253Google Scholar
  15. Helpap B, Böcking A, Dhom G, Faul P, Kastendieck H (1985) Klassifikation, histologisches und zytologisches Grading sowie Regressionsgrading des Prostatakarzinoms. Pathologe 6:3–7PubMedGoogle Scholar
  16. Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and PAP. J Histochem Cytochem 29:577–580PubMedGoogle Scholar
  17. Huvos AG, Rosen G, Marcove RC (1977) Primary osteogenic osteosarcoma. Arch Pathol Lab Med 101:14–18PubMedGoogle Scholar
  18. Junker K, Krapp D, Müller KM (1994) Morphological changes in small cell bronchial carcinoma after neoadjuvant chemotherapy. In: Antypas G (ed) Proceedings of the 16th International Cancer Congress, Monducci, Bologna, 1994. pp 133–136Google Scholar
  19. Junker K, Krapp D, Müller KM (1995) Kleinzelliges Bronchialkarzinom nach Chemotherapie — Morphologische Befnde. Pathologe 16:217–222PubMedGoogle Scholar
  20. Kaplan EL, Meier P (1958) Non-parametrics estimation from incomplete observations. J Am Statist Assoc 53:457–481Google Scholar
  21. Klurfeld DM (1985) Identification of foam cells in human atherosclerotic lesions as macrophages using monoclonal antibodies. Arch Pathol Lab Med 109:445–449PubMedGoogle Scholar
  22. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Ollivier JM, Bonvalot S, Gignoux M (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 73:2680–2686PubMedGoogle Scholar
  23. Mould RF, Williams RJ (1982) Survival of histologically proven carcinoma of the lung registered in the North-West-Thames region. Br J Cancer 40:999–1003Google Scholar
  24. Mountain CF (1986) A new international staging system for lung cancer. Chest [Suppl] 89:225s-232sPubMedGoogle Scholar
  25. Mountain CF (1994) Surgery for stage IIIa-N2 non-small cell lung cancer. Cancer 73:2589–2598PubMedGoogle Scholar
  26. Müller KM, Junker K, Wiethege T (1995) Nichtkleinzellige Bronchialkarzinome — Morphologie, Tumorregression, Molekularpatholgie. Onkologe 1:429–440Google Scholar
  27. Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, Bertoni F, Guerra A, Capanna R, Albisinni U, Galletti S, Gherlinzoni F, Calderoni P, Sudanese A, Baldini N, Bernini M Jaffe N (1985) Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Cancer 56:1515–1521PubMedGoogle Scholar
  28. Pisters KMW, Kris MG, Gralla RJ (1990) Preoperative chemotherapy in stage IIIA non-small cell lung cancer: an analysis of a trial in patients with clinically apparent mediastinal node involvement. In: Salmon SE (ed) Adjuvant therapy of cancer. Saunders, Philadelphia, pp 133–137Google Scholar
  29. Pisters KMW, Kris MG, Gralla RJ, Zaman MB, Heelan RT, Martini N (1993) Pathologic complete response in advanced non-small cell lung cancer following preoperative chemotherapy: implications for the design of future non-small cell lung cancer combined modality trials. J Clin Oncol 11:1757–1762PubMedGoogle Scholar
  30. Roessner A, Krüger KH, Ritter J, Urbanitz D (1986) Zur Morphologie des Ewing-Sarkoms nach primärer Chemotherapie. GBK-Mitteilungsdienst 49:28–33Google Scholar
  31. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330:153–158PubMedGoogle Scholar
  32. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of tumor to preoperative chemotherapy. Cancer 49:1221–1230PubMedGoogle Scholar
  33. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, Atkinson EN, Hong WK (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86:673–680PubMedGoogle Scholar
  34. Rusch VW (1993) Neoadjuvant chemotherapy for stage III lung cancer. Semin Thorac Cardiovasc Surg 5:258–267PubMedGoogle Scholar
  35. Salzer-Kuntschik M, Brand G, Delling G (1983) Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologe 4:135–141PubMedGoogle Scholar
  36. Schaffner T, Taylor K, Bartucci EJ (1980) Arterial foam cells with distinctive immunomorphologic and histologic features of macrophages. Am J Pathol 100:57–80PubMedGoogle Scholar
  37. Sherman D, Strauss G, Schwartz J (1987) Combined modality therapy for regionally advanced stage III non-small cell carcinoma of the lung (NSCLC) employing neo-adjuvant chemotherapy (CT), radiotherapy (RT), and surgery (S). Proc Am Soc Clin Oncol 6:167Google Scholar
  38. Shields TW, Higgins GA, Lawton R (1970) Preoperative X-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma. J Thorac Carciovasc Surg 59:49–61Google Scholar
  39. Skarin A, Jochelson M, Sheldon T (1989) Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 40:266–274PubMedGoogle Scholar
  40. Strauss G, Sherman L, Mathisen D (1988) Concurrent chemotherapy (CT) and radiotherapy (RT) followed by surgery (S) in marginally resectable stage III non-small cell carcinoma of the lung (NSCLC): a Cancer and Leukemia Group B study. Proc Am Soc Clin Oncol 7:203Google Scholar
  41. Sulfaro S, Frustaci S, Volpe R, Barzan L, Comoretto R, Monfardini S, Carbone A (1989) A pathologic assessment of tumor residue and stromal changes after intraarterial chemotherapy for head and neck carcinomas. Cancer 64:994–1001PubMedGoogle Scholar
  42. Thomas M, Macha HN, Rübe C, Loo J van de (1995) Stellenwert der Chemotherapie in der multimodalen Behandlung des nichtkleinzelligen Bronchialkarzinoms. Dtsch Med Wochenschr 120:1627–1630PubMedGoogle Scholar
  43. Thomas M, Eiff M von, Rübe C, Klinke V, Diederich S, Loo J van de (1996) Erfolgreiche multimodale Behandlung eines lokal weit fortgeschrittenen nicht-kleinzelligen Bronchialkarzinoms. Dtsch Med Wochenschr 121:658–662PubMedGoogle Scholar
  44. Weiden P, Piantadosi S (1988) Preoperative Chemoradiotherapy in stage III non-small cell lung cancer (NSCLC): A phase II study of the lung cancer study group (LCSG). Proc Am Soc Clin Oncol 7:197Google Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • K. Junker
    • 1
  • M. Thomas
    • 2
  • K. Schulmann
    • 1
  • F. Klinke
    • 3
  • U. Bosse
    • 4
  • K. -M. Müller
    • 1
  1. 1.Institute of PathologyBergmannsheil-University HospitalBochumGermany
  2. 2.Department of Internal Medicine AUniversity HospitalMünsterGermany
  3. 3.Department of Thoracic SurgerySt. Elisabeth HospitalIbbenbürenGermany
  4. 4.Institute of PathologyOsnabrückGermany

Personalised recommendations